Allergan Spends $90 Million to Buy Company Developing “Topical Botox”
Still hot off the heels of its historic merger at the end of last year with Pfizer, Allergan announced today that it will purchase Anterios, Inc., a clinical-stage biopharmaceutical company that is developing what they refer to as “a next-generation delivery system and botulinum toxin–based prescription products.”
It all sounds very futuristic, but what makes this particularly interesting is that Allergan (which is best-known as being the maker of Botox) will now be in business with a company that has a “proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.” In other words, something that sounds a lot like a topical type of Botox.
You May Also Like: The Truth Behind Kim Kardashian's "Organic Botox"
According to the official Allergan release, executive vice president David Nicholson said the acquisition "demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further extend our already deep neurotoxin pipeline by advancing a new delivery system and formulations that are appealing to both patients and physicians."
"Allergan is once again showing their commitment to aesthetics by purchasing Anterios and acquiring the global rights to ANT–1207," Montclair, NJ, dermatologist Jeanine B. Downie, MD, says. "The absolutely awesome potential of these two products is thrilling for patients that are looking for non-invasive approach is to treat their aesthetic and dermatologic conditions. An enhanced delivery system would be of great interest to physicians, as well as to the general public. I do believe these acquisitions will bring more people that are considering cosmetic procedures into their doctors' offices for treatment."